AbbVie Presents Results of Navitoclax + Ruxolitinib in P-II (REFINE) Trial for the Treatment of Myelofibrosis at AACR 2022
Shots:
- The P-II (REFINE) trial evaluates navitoclax + ruxolitinib in patients with myelofibrosis who had progressed on or had a suboptimal response to 12wks. of ruxolitinib monothx.
- In an exploratory analysis of 32 patients, 12 (38%) had a ≥ 1-grade improvement, 26 were evaluable for driver gene VAF reduction & 6 (23%) achieved a ≥20% reduction @24wk., 5 achieved BMF & VAF responses, m-OS was not reached for patients who had a ≥ 1-grade improvement in BMF or ≥20% driver gene VAF reduction over 28.5mos. who did not experience an improvement
- Additionally, 100% experienced 1 AEs & 15 (44%) SAE, no SAEs of bleeding & thrombocytopenia was manageable & reversible with dose reduction of navitoclax & ruxolitinib
Ref: PR Newswire | Image: AbbVie
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.